Andrew Roberts
Contributor since: 2018
Company: Louisiana biomedical research network
Latest Articles
BioTelemetry Tops The List Of 2019 M&A Candidates
Health Insurance Innovations - Buy Rating Reiterated As Addressable Market Poised To Double Into New Year
Green Days Ahead For Corcept With Victory Over Teva
Health Insurance Innovations Tops Healthcare Sector Growth Prospects As New Legislation Takes Effect
More Volatility Ahead For Arbutus Biopharma
Recro Pharma: Cautious Cheer Following Earnings
New FDA Biosimilars Action Plan Poses No Material Threat To Biologic Producers
Should You Buy Corcept Therapeutics Before Earnings?
AMAG Pharmaceuticals: Shift In Long Sentiment Following 60% Run Up
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
Johnson & Johnson: Wait For The Outcome
Health Insurance Innovations Set To Excel On Changes To Healthcare Policy
Recro Pharma: No Relief If New Data Is Needed
Get In While It's Down: Exelixis Is Seizing Oncological Market Space
Update: Corcept Therapeutics Remains A Strong Buy
Update: Endo Pharmaceuticals Will Be Crushed By Opioid Litigation
Concert Therapeutics Will See A Second Wind In Coming Months
Endo Pharmaceuticals Will Be Crushed By Opioid Litigation
J&J Will Continue To Suffer As Long As Scott Gottlieb Is In Charge Of The FDA
Axovant Sciences: 5 Trials, 4 Failures - Expect A Fifth
Corcept Therapeutics Tanked 32% By Trivial Teva Generic Filing, Once In A Blue Moon Biotech Opportunity
Pro-Dex: Cash Cow Quietly Enters Developing But Lucrative Surgical Robotics Market
Recro Pharma May Be The Key To The Opioid Epidemic
CorMedix Drug Candidate Lauded By FDA, Approved In The EU, Could Treat Deadly Pathogen Feared By CDC
Under Trump And Gottlieb, Small- And Mid-Cap Biotechs Are A Better Bet Than Large Caps
AMAG Pharmaceuticals Could Be February's Breakout Biopharma Stock
Galectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300%